Exclusive Online Content
SWK Holdings’ Subsidiary, Enteris BioPharma, Receives $5-Million Milestone Payment From Cara Therapeutics
SWK Holdings Corporation recently announced its wholly owned subsidiary, Enteris BioPharma, received a $5- million milestone payment from Cara Therapeutics related to the license agreement for Peptelligence….
ESCP Models – Hepatitis C Medications (Part 3), Commercial Impact
In this final installment, Josef Bossart, PhD, analyzes annual sales of products in the HCV treatment market and provides a quantitative perspective to the qualitative seesaws of the first two articles…..
SGS Acquires Quay Pharma to Further Strengthen Offering
Quay Pharma, the leading pharmaceutical contract development and manufacturing organization (CDMO), has been acquired by SGS, the Swiss-based world leading….
WACKER & CordenPharma Develop Solutions for Formulating Lipid Nanoparticles, Expanding Their Portfolio for Advanced Medicines
WACKER and CordenPharma have signed a development partnership in the field of Lipid Nanoparticle formulation. The two companies announced they plan to jointly develop know-how…
Immatics & Bristol Myers Squibb Enter Global Exclusive License for TCR Bispecific Program IMA401
Immatics N.V. and Bristol Myers Squibb recently announced they have entered into a license, development, and commercialization agreement for Immatics’ TCR Bispecific candidate, IMA401…..
TheraPanacea & Biogen Announce New Collaboration With the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
Biogen Inc. and TheraPanacea recently announced they have entered into a collaboration focused on multiple therapeutic areas in neuroscience, to further build on the companies’ existing relationship…..
HiberCell to Collaborate With Merck on Phase 2 Clinical Trial of Odetiglucan in Combination With KEYTRUDA in Patients With Metastatic Breast Cancer
HiberCell recently announced a clinical trial collaboration with Merck. This metastatic breast cancer clinical trial evaluates KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with….
Vaccitech Acquires Avidea Technologies to Expand Product Pipeline & Strengthen Scientific Leadership in Immunotherapies & Vaccines
Vaccitech plc recently announced that it has acquired US-based Avidea Technologies, Inc. The consideration to Avidea’s existing shareholders is $40 million….
Pfizer to Acquire Arena Pharmaceuticals for $6.7 Billion
Pfizer Inc. and Arena Pharmaceuticals, Inc. recently announced the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical-stage company developing….
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
Precision BioSciences, Inc. recently announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion (eLD) presented at….
Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination With Pembrolizumab in Metastatic Breast Cancer
Intensity Therapeutics, Inc. recently reported safety, pharmacokinetic, biomarker, and efficacy data using INT230-6, with and without pembrolizumab, in heavily pretreated refractory breast cancer patients as part of the….
Fareva & ApiJect Sign Licensing Agreement to Create a France-Based 500-Million Unit Annual Capacity for Single-Dose Prefilled Vaccine Injections
Fareva and ApiJect Systems, Corp. recently announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish more than 500 million doses per year of vaccines and….
BrainStorm Cell Therapeutics & Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing
BrainStorm Cell Therapeutics Inc. and Catalent recently announced that the technology transfer for NurOwn manufacturing at Catalent’s facility has been finalized….
Salubrent Pharma Solutions Strengthens Analytical Team
Salubrent Pharma Solutions recently it is continuing to build upon its vision of becoming a full service, technology-focused CDMO by filling the positions of Director of Analytical Development and Analytical Development Chemist at….
Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge With Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company
Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. recently announced they have entered into a definitive business combination agreement…..
Fortress Biotech, Cyprium Therapeutics & Sentynl Therapeutics Announce the Initiation of Rolling Submission of an NDA for Treatment of Menkes Disease
Cyprium Therapeutics, Inc., a Fortress Biotech, Inc. partner company, with support from its licensing partner Sentynl Therapeutics, Inc., a wholly owned subsidiary of Cadila Healthcare Limited, recently announced the initiation of a rolling submission of a New Drug Application….
Operations Commence at Genezen’s Lenti- & Retroviral Vector Process Development Lab
Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has officially….
ASLAN Pharmaceuticals & IQVIA Biotech Enter Strategic Collaboration
ASLAN Pharmaceuticals recently announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred….
NGM Bio Announces Clinical Trial Collaboration With Merck Related to Ongoing Phase 1/2 Trial of an ILT2/ILT4 Dual Antagonist Antibody in Combination With Merck’s KEYTRUDA
NGM Biopharmaceuticals, Inc. recently announced a clinical trial collaboration and supply agreement with Merck to evaluate NGM707, NGM’s wholly owned novel ILT2/ILT4 dual antagonist antibody, in combination with….
Ventyx Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis
Ventyx Biosciences, Inc. recently announced the first patient has been dosed in a Phase 2 randomized, placebo-controlled trial of VTX002 for the treatment of moderate-to-severe ulcerative colitis (UC)…..
